Substance Use Treatment During Pregnancy in New Jersey

Why this page exists, and what it can't do

Pregnancy adds real medical complexity to substance use treatment, and searching for information on the topic can turn up conflicting or alarming claims. This page cannot tell any individual what treatment approach is appropriate for their pregnancy, what dose of any medication is right, or when it's safe to change a course of treatment — those are questions only a qualified prescriber or clinician working directly with the patient can answer, with full knowledge of her medical history. What this page can do is explain, in general terms, why pregnancy changes the conversation, point to real guidance from medical organizations, and describe confidentiality protections that are often misunderstood.

If you are pregnant and using any substance, including alcohol, opioids, or a prescribed medication you're considering stopping, the single most useful step is talking to an obstetric provider or a substance use treatment provider as soon as possible — not searching for a general answer online, and not trying to manage it alone.

Why abrupt withdrawal during pregnancy carries its own risk

For some substances, particularly opioids, medical guidance specifically discourages sudden, unsupervised withdrawal during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) has stated that for pregnant women with opioid use disorder, medically supervised treatment with an opioid agonist medication is generally recommended over unsupervised withdrawal, because withdrawal without medical support is associated with high relapse rates and can worsen outcomes for both the pregnant person and the pregnancy (ACOG Committee Opinion on Opioid Use and Opioid Use Disorder in Pregnancy).

This is exactly the kind of decision that needs to be made with a clinician who knows the full clinical picture — this page is not telling any reader what to do, only that "just stopping" is not automatically the safest option for every substance and every pregnancy, and that professional guidance matters more here than almost anywhere else in this topic area.

Universal screening and why it's designed to be non-judgmental

ACOG recommends that screening for substance use be a routine, universal part of prenatal care — offered to every patient at the first prenatal visit, not just to patients a provider suspects might have a problem. The stated reasoning is that screening based only on assumptions or risk factors can miss real cases and can add to stigma for patients who are screened based on stereotypes rather than universally (ACOG Committee Opinion on Opioid Use and Opioid Use Disorder in Pregnancy).

If a provider raises the topic of substance use during a prenatal visit, that is a normal, expected part of standard care in this framework — not a sign that something is being assumed about a specific patient.

Confidentiality: what 42 CFR Part 2 covers

Substance use treatment records carry a specific layer of federal confidentiality protection beyond standard medical privacy law. Under 42 CFR Part 2, federally assisted programs that provide substance use disorder diagnosis, treatment, or referral generally cannot share information that identifies someone as having a substance use disorder without that person's written consent, except in narrow circumstances like a medical emergency or a court order (U.S. Department of Health and Human Services, Understanding Confidentiality of Substance Use Disorder Patient Records).

The rules are genuinely technical, and how they interact with prenatal care, hospital records, or child welfare reporting requirements can vary by situation and by state. This page is not a substitute for legal advice — if confidentiality is a specific concern for you, it is worth asking the treatment program directly how they apply Part 2 in practice, and considering a conversation with an attorney if the stakes feel high.

Why disclosing pregnancy early to any provider matters

Whether you're already in treatment or considering it, telling any provider — an obstetric provider, a prescriber, or a treatment program — that you are pregnant, as early as you're able to, allows care to be adjusted to your specific situation. Providers may need to change screening tools, monitoring frequency, or how they coordinate with other clinicians once pregnancy is part of the picture.

This isn't about disclosing to satisfy a rule; it's practical. A provider who doesn't know about a pregnancy cannot account for it in whatever care they're already providing.

Questions to ask a program or provider

If you're evaluating a treatment program while pregnant, these are reasonable, direct questions to ask rather than assuming any program has specific experience with pregnancy.

• Does the program have staff or a coordinating obstetric provider experienced in treating pregnant patients specifically?
• How does the program coordinate between substance use treatment and prenatal care?
• What is the program's approach to confidentiality, including how it applies 42 CFR Part 2 in practice?
• How does the program handle communication with a hospital or delivery team if that becomes relevant?
• What does the program's plan look like for care after delivery, not just during pregnancy?

Where to find guidance and support

SAMHSA and ACOG both publish public guidance specifically about treating pregnant and parenting people with substance use disorders, written for clinicians but useful background reading for patients and families too. SAMHSA's national helpline (1-800-662-4357) can also help connect callers to treatment referral information. If you need to talk through options, our line can help point you toward questions to ask and resources to look into — we do not provide treatment or make clinical recommendations ourselves.